Program Director/Principal Investigator (Last, First, Middle):
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Deirdre A. Hill
Research Assistant Professor
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing,
include postdoctoral training and residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
(if
MM/YY
FIELD OF STUDY
applicable)
University of Washington, Seattle, Washington
Ph.D.
6/97
Epidemiology
University of California, Los Angeles, California
M.P.H.
6/85
Epidemiology
University of California, Santa Barbara, California
B.A.
6/83
Biological Sciences
NOTE: The Biographical Sketch may not exceed four pages. Follow the formats and instructions below.
A.
Personal Statement
An important focus of my work is to develop greater understanding of the 1.6-fold increased risk of breast cancer death
among Hispanic vs. non-Hispanic women in New Mexico, the largest known such disparity in Hispanics. As part of an
NIH-funded R01, we are currently collecting demographic, socioeconomic, and breast cancer risk factors, mammography
screening details, and extensive treatment, comorbidity, and late effects information from the medical charts of over 2000
women to comprehensively address this question and identify possible prevention strategies. In addition, we are
constructing tissue microarrays to examine tumor aggressiveness markers, and collecting DNA to assess ancestry markers
to appropriately classify and account for Hispanic ethnicity.
Building on previous work at UNM, I have assembled what may be one of the largest known cohorts of women with
premalignant breast disease (n=16,000), and am following them for breast cancer. Through examination of tissue
biomarker expression, this study is poised to make a vital contribution to identification of women at short-term high-risk
of breast cancer, and may facilitate discovery of markers leading to earlier detection. With funding from a private
foundation, we are examining expression of protein biomarkers in the breast tissue of 100 women who developed breast
cancer within 60 months of biopsy, and 300 matched controls who did not.
Another primary focus of my work is a series of collaborations within the Breast Cancer Surveillance Consortium (BCSC),
which provide rich opportunities to contribute to the vital goals of optimizing breast cancer screening strategies, and
improving radiologist interpretation of mammograms. As a co-investigator on the BCSC “Risk-Based Breast Cancer
Screening in Community Settings”, an NIH PO1, I am overseeing assessment of mammography and MRI utilization in
comparison with national guidelines. In the BCSC-initiated randomized clinical trial, “Strategies to Improve the Accuracy
of Mammographic Interpretation“, which was funded by the American Cancer Society, we have recently completed an
intervention that was modestly effective in improving mammogram assessment. As principal investigator of the NM
Mammography Project, a BCSC effort that began in NM in 1992, I facilitate ongoing data analyses at the local and
consortia level. The following pages summarize my work:
Program Director/Principal Investigator (Last, First, Middle):
B.
Positions and Honors
1992 -1993
1992 -1993
1993 -1997
1997 - 2000
2000 - 2004
2004-present
Statistical Consultant, United Nations Truth Commission and Ad Hoc Commission on Human Rights in
El Salvador, Washington, D.C., and Human Rights Department, El Rescate, Los Angeles, CA.
Research Associate, Case-Control Study of Breast Cancer in Young Women, Fred Hutchinson Cancer
Research Center, Seattle, WA.
Research Associate, Case-Control Study of Endometrial Cancer, Fred Hutchinson Cancer Research
Center, Seattle, WA.
Breast Cancer Traineeship, University of Southern California School of Medicine, Preventive
Medicine, Los Angeles, CA.
Senior Fellow, Radiation Epidemiology Branch. Division of Cancer Epidemiology and Genetics,
National Cancer Institute, Bethesda, MD.
Research Assistant Professor, Division of Epidemiology, Dept of Internal Medicine. University of New
Mexico, Albuquerque, NM.
Professional Recognition and Honors
 Radiation Research Society, Scholar-in-Training Award, 2003
 Fellowship Achievement Award. Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Bethesda, MD, 2002
 Outstanding Student Award at Graduation, University of Washington, Seattle, Department of Epidemiology,1997
 National Research Service Award for Training in Cancer Epidemiology and Biostatistics,1993-1997
 Achievement Rewards for College Scientists (ARCS) Foundation, Epidemiology Department
Scholarship Award, University of Washington, Seattle,1992-1995
 Delta Omega Public Health Honor Society, Student Award for Outstanding Paper,1992
 Academic Scholarship Award, Division of Public Health, University of California, Los Angeles,1983
C.
Peer-reviewed Publications (15 selected of 34)
1. Hill DA, Weiss N, Voigt L, Beresford S, Daling J, Stanford J, Self S. Continuous Combined Hormone
Replacement Therapy and Risk of Endometrial Cancer. Am J Ob Gyn 183:1456-61, 2000
2. Hill DA, Preston-Martin S, Ross R, Bernstein L. Medical Radiation, Family History of Cancer, and Benign Breast
Disease in Relation to Breast Cancer Risk in Young Women. Cancer Causes Control 13:711-18, 2002
3. Hill DA, Gridley G, Cnattingius S, Mellemkjaer L, Linet M, Adami H-O, Olsen JH, Nyren O, Fraumeni JF Jr.
Mortality and Cancer Incidence among Individuals with Down Syndrome. Arch Int Med 163:705-11, 2003
4. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Clarke AE, Glimelius B, Andersson M,
Wiklund T, Lynch CF, Glimelius I, Holowaty E, Storm H, Pukkala EM, Curtis R, Stovall M, Boice JD, Gilbert
E. Breast Cancer Following Radiotherapy and Chemotherapy among Young Women Treated for Hodgkin's
disease. JAMA 290:465-475, 2003
5. Schairer C, Hill DA, Sturgeon S, Fears T, Pollak M, Mies C, Ziegler R, Hoover R, Sherman M. Serum Levels of
IGF-I, IGFBP-3, and c-Peptide and Risk of Benign Breast Hyperplasia and Breast Cancer in Post-Menopausal
Women. Int J Cancer 20:108:773-779, 2004
6. Allan JM., Smith AG., Wheatley K, Hills RK, Travis LB, Hill DA, Swirsky DM, Roman E, Morgan GJ,
Wild CP. The Xeroderma Pigmentosum group D codon 751 polymorphism associates with treatment
outcome and risk of acute myeloid leukaemia after chemotherapy. Blood 2004; 104:3872
Program Director/Principal Investigator (Last, First, Middle):
7. Reed SD, Voigt LF, Beresford SA, Hill DA, Doherty JA, Weiss NS. Dose of progestin in
postmenopausal combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol
2004;191:1146-51.
8. Schairer C, Hill DA, Sturgeon S, Fears T, Pollak M, Mies C, Ziegler R, Hoover R, Sherman M. Serum Levels of
Estrogens and Androgens and Risk of Benign Breast Hyperplasia in Post-Menopausal Women. Cancer Epi
Biomarkers Prevention 14: 322-327, 2005
9. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M,
Wiklund T, Lynch CF, Pee D, Smith SA, Van’t Veer MB, Pukkala EM, Storm H, Stovall M, Gilbert E, Gail MH.
Cumulative Absolute Breast Cancer Risk For Young Women Treated For Hodgkin Lymphoma. JNCI 97: 1428 –
37, 2005
10. Hill DA, Gilbert E, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M,
Wiklund T, Lynch CF, Glimelius I, van’t Veer M, Storm H, Pukkala EM, Curtis R, Allan JM, Stovall M, Boice
JD. Breast Cancer Risk Following Radiotherapy for Hodgkin Lymphoma: Modification by Other Risk Factors.
Blood 106:411-417, 2005
11. Kolb B, Wallace AM, Hill DA, Royce M. Disparities in Cancer Care among Racial and Ethnic Minorities.
Oncology 20:1256-61, 2006
12. Hill DA, Wang SS, Cerhan JR, Davis S, Cozen W, Severson RK, Hartge P, Wacholder S, Yeager M, Chanock SJ,
Rothman N. Risk of Non-Hodgkin Lymphoma (NHL) in Relation to Germline Variation in DNA Repair and
Related Genes. Blood 108:3161-7, 2006
13. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman
N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LF, Lim U, Lynch CF,
Schenk M, Wacholder S, Ward M, Zahm SH, Chanock SJ, Cerhan JR, Hartge P. Etiologic Heterogeneity Among
Non-Hodgkin Lymphoma Subtypes. Blood 112:5150-60, 2008
14. Hill, DA, Nibbe A, Royce ME, Wallace AM, Kang H, Wiggins CL, Rosenberg RD. Method of Detection and
Breast Cancer Survival Disparities in Hispanic Women. Cancer Epidemiol Biomarkers Prev 19::2453-60, 2010
15. Ziogas A, Horick NK, Kinney AY, Lowery JT Domcheck S, Isaccs C, Griffin CA, Moorman PG, Edwards KL,
Hill DA, Berg JS, Tomlinson GE, Strong LC, Anton-Culver H, Finkelstein DM, Plon SE. Clinically Relevant
Changes in Family History of Cancer over Time. JAMA 13:172-8, 2011
D. Research Support
ACTIVE
SIRGS-06-281-01 Hill (PI)
8/1/06 – 3/31/13
Strategies to Improve the Accuracy of Mammographic Interpretation
The purpose of this study is to better understand the factors associated with radiologist performance, to create an
instrument that predicts radiologist performance, and to create an intervention to improve mammography
performance.
R01 CA132877 Hill (PI)
01/1/10-12/31/14
Towards a Transdisciplinary Understanding of Breast Cancer Survival Disparities
Program Director/Principal Investigator (Last, First, Middle):
The major goal of this study is to comprehensively investigate factors related to the disproportionate breast cancer
mortality in Hispanic as compared to non-Hispanic White women in New Mexico, and to determine the contribution
of each to the disparate survival.
P50CA148143 Thompson (PI)
5/1/10-04/30/15
Understanding and Preventing Breast Cancer Disparities in Latinas
The goal of this P50 application to understand the antecedents of breast cancer in the Latina population, to understand
the types of breast cancer found in the Latina population, and develop and implement a comprehensive program of
screening to increase the opportunities for early detection among Latinas.
P01 CA154292 Miglioretti/Kerlikowske(PI) 9/1/11-8/30/16
Risk-Based Breast Cancer Screening in Community Settings
The major goals of this project are to develop improved breast cancer risk prediction models, to characterize
performance measures of advanced breast imaging technologies by patient factors, to understand how access and
utilization of breast imaging is associated with risk, and to identify optimal breast cancer screening strategies by risk
profile.
COMPLETED
NIH/NCI 5R01CA125194 Kinney (PI)
11/1/10- 4/31/11
Impact of Remote Familial Colorectal Cancer Risk Assessment and Counseling
The goal of this study is to determine whether first-degree relatives of colon cancer patients will change screening
practices after receipt of a telephone-based intervention from a certified genetic counselor, vs. receipt of a risk
information brochure. Specific aims include assessment of screening practices and colon cancer risk factors at baseline,
and evaluation of behavior change following the intervention.
AF10907
Hill (PI)
5/01/08-12/31/11
Tumor markers in premalignant breast tissue and risk of subsequent breast cancer.
The goal of this project is to identify biomarkers of short-term subsequent breast cancer risk in breast tissue specimens
of women who have received a benign biopsy.
AF10550
Hill (PI)
10/01/07-11/01/09
Mammographic screening and breast cancer survival disparities in NM Hispanic Women: A population-based study.
Using New Mexico Mammography Project data linked to over 5000 SEER breast cancer records, we examined the role
of method of cancer detection in relation to breast cancer survival differences.